Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 21Neurofibromatosis 1 19Neurofibroma, Plexiform 11Melanoma 11Lung Neoplasms 8Neoplasms 7Neoplasm Metastasis 7Colorectal Neoplasms 7Breast Neoplasms 7Solid Tumours 5Pancreatic Neoplasms 5Carcinoma, Hepatocellular 4Uveal Melanoma 3Triple Negative Breast Neoplasms 3Thyroid Neoplasms 3Rectal Neoplasms 3Neurofibrosarcoma 3Gallbladder Neoplasms 3Colonic Neoplasms 3Biliary Tract Neoplasms 3Thyroid Cancer, Papillary 2Sarcoma 2Bile Duct Neoplasms 2Adult Solid Neoplasm 2Thyroid Diseases 1Thymoma 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma, Kaposi 1Renal Insufficiency 1

Interventions

Bevacizumab 3pralsetinib 2pembrolizumab 2osimertinib 2contrast agent BR1 2Pemetrexed 2Oncolytic Virotherapy 2Carboplatin 2vorasidenib 1lutetium Lu 177 dotatate 1keyhole-limpet hemocyanin 1interferon gamma-1b 1copper dotatate CU-64 1Vaccines 1Temozolomide 1Sunitinib 1Stem Cell Transplantation 1Paclitaxel 1Microbubbles 1Lutetium-177 1Lutetium 1Interleukin-12 1Interferon-gamma 1Immunotherapy 1Gemcitabine 1Cisplatin 1Biopsy 1Antibodies, Monoclonal 1AZD 6244 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Nerve Tissue × AZD 6244 × Clear all
NCT03109301 2019-04-05

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn
CNS

Neoplasms, Nerve Tissue, Neurofibromatosis 1, Peripheral Nervous System Diseases, Neurofibroma, Plexiform, Heredodegenerative Disorders, Nervous System

Data powered by HemOnc (CC BY 4.0) Colophon âš¡